Search

Your search keyword '"Harvey, Ruth"' showing total 224 results

Search Constraints

Start Over You searched for: Author "Harvey, Ruth" Remove constraint Author: "Harvey, Ruth" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
224 results on '"Harvey, Ruth"'

Search Results

1. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.

4. Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

7. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

8. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study

9. Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

11. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

12. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

13. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

14. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.

15. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

16. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus

17. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain

19. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.

21. 34 COVID-19 caused by either Omicron sub-variants or Delta in non-hospitalised adults associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history

22. 33 Fourth dose bivalent mRNA vaccines containing BA.1 significantly augment neutralising antibody titres against SARS-COV-2 Omicron sub-lineages XBB and BQ.1.1 in healthy adults

23. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.

24. A case of swine influenza A(H1N2)v in England, November 2023.

25. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

26. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

28. Bertran de Born and Raimon de Planell.

29. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

31. Three-dose vaccination elicits neutralising antibodies against omicron

32. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

33. The development of vaccine viruses against pandemic A(H1N1) influenza

35. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

37. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

38. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

39. SARS-CoV-2 mucosal neutralising immunity after vaccination

44. Short Notices

45. Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

47. LITERATURE

49. Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies.

50. SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export.

Catalog

Books, media, physical & digital resources